Dopamine transporter binding in symptomatic controls and healthy volunteers : Considerations for neuroimaging trials

Show full item record



Permalink

http://hdl.handle.net/10138/336996

Citation

Honkanen , E A , Eklund , M , Nuuttila , S , Noponen , T , Jaakkola , E , Mäkinen , E , Hirvilammi , R , Seppänen , M , Lindholm , K , Scheperjans , F , Parkkola , R , Joutsa , J , Varrone , A & Kaasinen , V 2021 , ' Dopamine transporter binding in symptomatic controls and healthy volunteers : Considerations for neuroimaging trials ' , NeuroImage: Clinical , vol. 32 , 102807 . https://doi.org/10.1016/j.nicl.2021.102807

Title: Dopamine transporter binding in symptomatic controls and healthy volunteers : Considerations for neuroimaging trials
Author: Honkanen, Emma A.; Eklund, Mikael; Nuuttila, Simo; Noponen, Tommi; Jaakkola, Elina; Mäkinen, Elina; Hirvilammi, Risto; Seppänen, Marko; Lindholm, Kari; Scheperjans, Filip; Parkkola, Riitta; Joutsa, Juho; Varrone, Andrea; Kaasinen, Valtteri
Contributor organization: HUS Neurocenter
Neurologian yksikkö
Date: 2021-01
Language: eng
Number of pages: 6
Belongs to series: NeuroImage: Clinical
ISSN: 2213-1582
DOI: https://doi.org/10.1016/j.nicl.2021.102807
URI: http://hdl.handle.net/10138/336996
Abstract: Objective: To evaluate possible differences between brain dopamine transporter (DAT) binding in a group of symptomatic parkinsonism patients without dopaminergic degeneration and healthy individuals. Background: Dopaminergic neuroimaging studies of Parkinson's disease (PD) have often used control groups formed from symptomatic patients with apparently normal striatal dopamine function. We sought to investigate whether symptomatic patients can be used to represent dopaminergically normal healthy controls. Methods: Forty healthy elderly individuals were scanned with DAT [123I]FP-CIT SPECT and compared to 69 age- and sex-matched symptomatic patients with nondegenerative conditions (including essential tremor, drug-induced parkinsonism and vascular parkinsonism). An automated region-of-interest based analysis of the caudate nucleus and the anterior/posterior putamen was performed. Specific binding ratios (SBR = [ROI-occ]/occ) were compared between the groups. Results: DAT binding in symptomatic patients was 8.6% higher in the posterior putamen than in healthy controls (p = 0.03). Binding correlated negatively with age in both groups but not with motor symptom severity, cognitive function or depression ratings. Conclusions: Putaminal DAT binding, as measured with [123I]FP-CIT SPECT, was higher in symptomatic controls than in healthy individuals. The reason for the difference is unclear but can include selection bias when DAT binding is used to aid clinical diagnosis and possible self-selection bias in healthy volunteerism. This effect should be taken into consideration when designing and interpreting neuroimaging trials investigating the dopamine system with [123I]FP-CIT SPECT.
Description: Publisher Copyright: © 2021 The Author(s)
Subject: Controls
Dopamine transporter
Healthy controls
SPECT
3112 Neurosciences
3124 Neurology and psychiatry
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2213158221002515_main.pdf 568.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record